The Department of Commerce is seeking more information about how current trade policies are impacting the U.S. medtech industry. The investigation could lead to the creation of new tariffs. Public comments are being accepted until Oct. 17, and the findings will be presented to President Donald Trump.

Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

The document provides an in-depth look at the close relationship between inflammation and cardiovascular disease. "The time for taking action has now arrived," the authors wrote. 

Thanks to AI, clinicians can use mammograms to do a lot more than identify signs of breast cancer. Researchers explored data from nearly 50,000 patients, presenting their findings in Heart.

The next-generation Watchman device is designed to better seal off complex LAA anatomy in a variety of LAA shapes and sizes.

The FDA-cleared device from Medtronic, which arrives pre-loaded on a single-use delivery system, is now set to launch in Europe.

Martha Gulati, MD, co-chair on a new joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology, discusses the dire need she sees to boost prevention efforts for heart failure.

The drug, already approved by the FDA to treat obstructive HCM, failed to outperform a placebo after 48 weeks.